文献速递乳腺MR

Oncotype DX复发评分的影像基因组学特征可预测雌激素受体阳性乳腺癌生存

Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor-Positive Breast Cancer: A Multicohort Study.
PubMed 文献 · Radiology · 2021-11-30

回顾性多队列研究基于术前动态增强MRI识别与Oncotype DX复发评分相关的影像基因组学特征(n=11),预测复发评分(R2=0.33,P<.001);预测复发评分大于29.9与较差的总生存和无复发生存相关(P=.001和P=.007),且预测复发评分在化疗反应良好者中更高(30.51±6.92 vs 27.35±4.04,P=.001);联合预测复发评分与互补特征预测新辅助化疗反应的AUC为0.85(P<.001)。

要点

  • 术前MRI纹理、形态和统计特征可生成预测Oncotype DX复发评分(R2=0.33,P<.001)。
  • 预测复发评分大于29.9与较差总生存和无复发生存相关(P=.001和P=.007)。
  • 联合预测复发评分与互补特征预测新辅助化疗反应AUC为0.85(P<.001)。

核心结论

  • 与基因组检测相关的影像基因组学特征为雌激素受体阳性乳腺癌提供了预后和治疗标志物。

研究设计与样本

  • 回顾性多队列研究,纳入影像基因组学开发数据集130例女性(平均年龄52岁±10)、预后评估数据集116例女性(平均年龄48岁±9)和治疗评估数据集135例女性(平均年龄50岁±11);开发数据集使用2016年1月至2019年10月间的术前动态增强MRI和复发评分数据,预后评估采用多变量Cox比例风险模型,治疗评估数据集来自2015年8月至2019年3月,预测性能用受试者工作特征曲线下面积(AUC)评估。

诊断标准与关键数值

  • 识别出11个纹理、形态和统计特征的影像基因组学特征用于生成预测复发评分(R2=0.33,P<.001);预测复发评分大于29.9与较差总生存(P=.001)和无复发生存(P=.007)相关;预测复发评分在新辅助化疗反应良好者中更高(反应者30.51±6.92 vs 无反应者27.35±4.04,P=.001);联合预测复发评分与互补特征预测新辅助化疗反应的AUC为0.85(P<.001)。

临床应用与阅片要点

  • 术前动态增强MRI的纹理、形态和统计特征可用于生成预测Oncotype DX复发评分,预测复发评分大于29.9与较差生存相关,联合预测复发评分与互补特征有助于预测新辅助化疗反应(AUC=0.85)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Radiogenomics explores the association between imaging features and genomic assays to uncover relevant prognostic features; however, the prognostic implications of the derived signatures remain unclear. Purpose To identify preoperative radiogenomic signatures of estrogen receptor-positive breast cancer associated with the Oncotype DX recurrence score (RS) and to evaluate whether they are biomarkers for survival and responses to neoadjuvant chemotherapy (NACT). Materials and Methods In this retrospective multicohort study, three data sets were analyzed. The radiogenomic development data set, with preoperative dynamic contrast-enhanced MRI and RS data obtained between January 2016 and October 2019 was used to identify radiogenomic signatures. Prognostic implications of the imaging signatures were assessed by measuring overall survival and recurrence-free survival in the prognostic assessment data set using a multivariable Cox proportional hazards model. The therapeutic implication of the radiogenomic signatures was evaluated by determining their ability to predict the response to NACT using the treatment assessment data set obtained between August 2015 and March 2019. Prediction performance was estimated by using the area under the receiver operating characteristic curve (AUC). Results The final cohorts included a radiogenomic development data set with 130 women (mean age, 52 years ± 10 [standard deviation]), a prognostic assessment data set with 116 women (mean age, 48 years ± 9), and a treatment assessment data set with 135 women (mean age, 50 years ± 11). Radiogenomic signatures (n = 11) of texture and morphologic and statistical features were identified to generate the predicted RS (R2 = 0.33, P < .001). A predicted RS greater than 29.9 was associated with poor overall and recurrence-free survival (P = .001 and P = .007, respectively); predicted RS was greater in women with a good NACT response (30.51 ± 6.92 vs 27.35 ± 4.04 [responders vs nonresponders], P = .001). By combining the predicted RS and complementary features, the model achieved improved performance in prediction of the NACT response (AUC, 0.85; P < .001). Conclusion Radiogenomic signatures associated with genomic assays provide markers of prognosis and treatment in estrogen receptor-positive breast cancer. © RSNA, 2021 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Fan, Cui, You, et al. Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor-Positive Breast Cancer: A Multicohort Study. Radiology. 2021. PMID: 34846204. doi:10.1148/radiol.2021210738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。